There are four opportunities to apply a Risk-Based Approach for Computer Systems Validation. These opportunities include utilizing risk to scale, supplier audit efforts, validation deliverables, testing and documentation levels. All...
Read More
A standardized process is a well-defined and structured set of activities built for conception through retirement. Process Standardization creates transparency across the lifecycle framework and enables management control. It establishes...
Read More
A well-defined Lifecycle Framework strategy is designed to create a uniform approach throughout the entire organization. The benefit of having a uniform approach reduces the amount of rework that will...
Read More
The pharmaceutical and medical device industry is a rapidly changing environment. Successful businesses are those who are able to stay on top of the newest trends and regulations while aligning...
Read More
The regulatory landscape is dynamic in nature, constantly evolving and changing at an accelerated pace. Keeping up with the changing regulations can be an uphill task for organizations in highly...
Read More
At EngiLifeSciences, we begin with an assessment process, and a part of the process is helping clients understand their strategic objectives. Following that, we conduct tailored studies at different levels...
Read More
Computer system validation (CSV) has become essential in the drug and medical device industry. The FDA defines process validation as "establishing documented evidence which provides a high degree of assurance...
Read More
Gregory W. Pierce, the CEO of EngiLifeSciences, has been a frontrunner in developing solutions that allow Medical Device, Pharmaceutical and Biotechnology Manufacturers to efficiently bring compliant and high-quality products to...
Read More
Increased recalls, pricing pressures and a changing regulatory environment, have many Life Science firms wondering how to prepare for the future. We’ve seen change in the horizon after the FDA...
Read More
The next 12 months will likely change the regulatory and compliance landscape for Life Sciences companies. An administration change coupled with a case for quality initiative will drive a new...
Read More